Cell and Gene Therapy Sector Needs to Automate

April 16, 2020 | Biotechnology

Reading time: 2-3 minutes

Sourced by Lab.Equipment from GEN, here is an interesting Bio Technology industry news for you:

Cell and gene therapy firms are not ready to fully embrace artificial intelligence (AI) says an official at the US subsidiary of Hitachi Chemical, who thinks developers and manufacturers must learn to automate production first. The Japanese conglomerate cemented its presence in the cell therapy contract manufacturing space in January with the opening of a facility in Allendale, NJ. The facility, which is operated by Hitachi Chemical Advanced Therapeutics Solutions (HCATS), is the first designed “to meet the unique needs of commercial cell and gene therapy products,” according to Thomas Heathman, PhD, HCATS’ business leader in North America.

These needs include being able to vary output, he continues, adding that it is harder to predict approval timelines and commercial demand for cell therapies than for other biopharmaceuticals... Find the full article at the GEN – Genetic Engineering and Biotechnology News Blog.

Working on Bio Technology applications like in situ hybridization or direct sequencing and scouting for reliable Bio tech lab equipment for your workroom? Shop Lab.Equipment’s extensive collection of biotech equipment produced by globally trusted MFGs like Radwag and AnD Weighing -- from pipettes, precision scales, to centrifuges and more here.

Dealing with other applications? We got you covered so no worries. Discover our selection of high quality lab equipment for cannabis, veterinary, environmental, applications and more.

Back To Top
We are fully compliant with the GDPR laws. We promise to safeguard your data and protect your privacy rights.